Wall Street brokerages expect Envista Holdings Co. (NYSE:NVST – Get Rating) to announce sales of $657.56 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Envista’s earnings, with the highest sales estimate coming in at $664.30 million and the lowest estimate coming in at $649.22 million. Envista reported sales of $740.10 million during the same quarter last year, which would suggest a negative year over year growth rate of 11.2%. The firm is expected to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Envista will report full year sales of $2.66 billion for the current financial year, with estimates ranging from $2.65 billion to $2.67 billion. For the next financial year, analysts anticipate that the firm will report sales of $2.87 billion, with estimates ranging from $2.83 billion to $2.94 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Envista.
Envista (NYSE:NVST – Get Rating) last issued its earnings results on Wednesday, May 4th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.03. The firm had revenue of $631.40 million for the quarter, compared to analysts’ expectations of $629.30 million. Envista had a net margin of 13.06% and a return on equity of 8.54%. The firm’s revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.54 earnings per share.
NVST stock traded up $0.76 on Thursday, hitting $42.09. The company’s stock had a trading volume of 1,260,766 shares, compared to its average volume of 1,876,091. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.22. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of 21.81, a price-to-earnings-growth ratio of 1.57 and a beta of 1.64. Envista has a 1 year low of $37.60 and a 1 year high of $52.03. The firm has a 50 day moving average of $45.29 and a two-hundred day moving average of $44.34.
In other Envista news, CFO Howard H. Yu sold 5,341 shares of the business’s stock in a transaction dated Monday, April 18th. The stock was sold at an average price of $45.73, for a total value of $244,243.93. Following the completion of the sale, the chief financial officer now owns 52,411 shares of the company’s stock, valued at $2,396,755.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mischa Reis sold 5,009 shares of Envista stock in a transaction dated Friday, February 25th. The stock was sold at an average price of $47.59, for a total value of $238,378.31. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 154,773 shares of company stock worth $7,564,998. Company insiders own 0.76% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Virtu Financial LLC increased its holdings in Envista by 111.6% during the 1st quarter. Virtu Financial LLC now owns 9,445 shares of the company’s stock worth $460,000 after purchasing an additional 4,981 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in Envista in the 1st quarter valued at about $36,982,000. Point72 Hong Kong Ltd acquired a new stake in Envista in the 1st quarter valued at about $1,812,000. Sandler Capital Management acquired a new stake in Envista during the first quarter worth approximately $8,305,000. Finally, Eaton Vance Management lifted its position in Envista by 7.2% during the first quarter. Eaton Vance Management now owns 2,187,720 shares of the company’s stock worth $106,563,000 after acquiring an additional 147,127 shares during the last quarter.
About Envista (Get Rating)
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands.
- Get a free copy of the StockNews.com research report on Envista (NVST)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.